Abstract
5-Hydroxytryptamine (5-HT; serotonin) can either cause vasodilatation or vasoconstriction with resulting increases in blood flow and decreases in blood pressure or vice versa [1]. This complexity can be explained by the interaction of the monoamine with different receptors within the vascular wall. On the one hand, activation of endothelial receptors by 5-HT will cause the release of a short-lived vasodilatator substance (EDRF: endothelium derived relaxing factor) and activation of 5-HT receptors on the adrenergic nerve endings will result in a decreased liberation of noradrenaline [2–7]. The receptors involved in these actions of 5-HT leading to vasodilatation belong to the 5-HT1-like type [4, 7–9]. On the other hand, 5-HT can cause vasoconstriction by activation of 5-HT2 receptors on the vascular smooth muscle cells [10–12]. Whether a particular vascular bed will respond to 5-HT with a vasodilatation or a vasoconstriction will ultimately depend upon a balance between factors which determine which of the two receptor systems can play a dominating role. It is the aim of this chapter to specifically review the evidence of pathological changes favouring the 5-HT2 receptor mediated vasoconstriction.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Page IH (1954): Serotonin (5-hydroxytryptamine). Physiol Rev 34: 563–588.
Furchgott RF (1983): Role of the endothelium in responses of vascular smooth muscle. Circ Res 53: 557–573.
Cocks RM, Angus JA (1983): Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin. Nature (Lond) 305: 627–630.
Cohen RA, Shepherd JT, Vanhoutte PM (1983): 5-Hydroxytryptamine can mediate endothelium-dependent relaxation of coronary arteries. Am J Physiol 245: H1077–H1080.
Vanhoutte PM (1987): Endothelium and the control of vascular tissue. NIPS 2: 18–22.
McGrath MA (1977): 5-Hydroxytryptamine and neurotransmitter release in canine blood vessels. Circ Res 41:428–435.
Cohen RA (1985): Serotonergic prejunctional inhibition of canine coronary adrenergic nerves. J Pharmacol Exp Ther 235: 76–80.
Houston DS, Shepherd JT, Vanhoutte PM (1985): Adenine nucleotides, serotonin and endothelium-dependent relaxations to platelets. Am J Physiol 248: H389–H395.
Engel G, Gothert M, Miiller-Schweinitzer E, Schlicker E, Sistonen L, Stadler PA (1983): Evidence for common pharmacological properties of [3H] 5-hydroxytryptamine binding sites, presynaptic 5-hydroxytryptamine autoreceptors in CNS and inhibitory presynaptic 5-hydroxytryptamine receptors on sympathetic nerves. Naunyn Schmiedeberg’s Arch Pharmacol 324: 116–124.
Van Nueten JM, Leysen JE, De Clerck F, Vanhoutte PM (1984): Serotonergic receptor subtypes and vascular reactivity. J Cardiovasc Pharmacol 6: S564–S574.
Van Nueten JM, Janssens WJ, Vanhoutte PM (1985): Serotonin and vascular reactivity. Pharmacol Res Commun 17: 585–608.
Van Nueten JM, Janssen PAJ, Symoens J, Janssens WJ, Heykants J, De Clerck F, Leysen JE, Vancauteren H, Vanhoutte PM(1987): Ketanserin, pp. 1–56 in: Scriabine A (ed.), New Cardiovascular Drugs. New York: Raven Press.
Starling LM, Bouillin DJ, Grahame-Smith DG, Adams CBT, Gye RS (1975): Responses of isolated human basilar arteries to 5-hydroxytryptamine, noradrenaline, serum, platelets, and erythrocytes. J Neurol Neurosurg Psychiatry 38: 650–656.
De Clerck F, Van Nueten JM (1982): Platelet-mediated vascular contractions: inhibition of the serotonergic component by ketanserin. Thromb Res 27: 713–727.
Cohen RA, Shepherd JT, Vanhoutte PM (1983): Inhibitory role of the endothelium in response of isolated coronary arteries to platelets. Science 221:273–274.
McGoon MD, Vanhoutte PM (1984): Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine. J Clin Invest 74: 828–833.
Vanhoutte PM (1985): Peripheral serotonergic receptors and hypertension, pp. 123–133 in: Vanhoutte PM (ed.), Serotonin and the Cardiovascular System. New York: Raven Press.
Vanhoutte PM, Houston DS (1985): Platelets, endothelium and vasospasm. Circulation 72: 728–734.
Van Nueten JM, Janssen PAJ, Van Beek J, Xhonneux R, Verbeuren TJ, Vanhoutte PM (1981): Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors. J Pharmacol Exp Ther 218: 217–230.
Garland CJ (1985): Endothelial cells and the electrical and mechanical responses of the rabbit coronary artery to 5’-hydroxytryptamine. J Pharmacol Exp Ther 233: 158–162.
Verbeuren TJ, Jordaens FH, Zonnekeyn LL, Van Hove CE, Coene MC, Herman AG (1986): Effect of hypercholesterolemia on vascular reactivity in the rabbit. 1. Endothelium- dependent and endothelium-independent contractions and relaxations in isolated arteries of control and hypercholesterolemic rabbits. Circ Res 58: 552–564.
Lamping KG, Dole WP (1987): Acute hypertension selectively potentiates constrictor responses of large coronary arteries to serotonin by altering endothelial function in vivo. Circ Res 61: 904–913.
Shimokawa H, Aarhus LL, Vanhoutte PM (1987): Porcine coronary arteries with regenerated endothelium have a reduced endothelium-dependent responsiveness to aggregating platelets and serotonin. Circ Res 61: 256–270.
Liischer TF, Vanhoutte PM (1986): Endothelium-dependent responses to platelets and serotonin in spontaneously hypertensive rats. Hypertension 8: II.55–II.60.
de la Lande IS, Cannell VA, Waterson JG (1966): The interaction of serotonin and noradrenaline on the perfused artery. Br J Pharmacol Chemother 28: 255–272.
Van Nueten JM, Janssen PAJ, De Ridder W, Vanhoutte PM (1982): Interaction between 5-hydroxytryptamine and other vasoconstrictor substances in the isolated femoral artery of the rabbit: effect of ketanserin (R 41 468). Eur J Pharmacol 77: 281–287.
Myers JH, Mecca TE, Webb RC (1985): Direct and sensitizing effects of serotonin agonists and antagonists on vascular smooth muscle. J Cardiovasc Pharmacol 1 (suppl. 7): S44 – S48.
Scroop GC, Walsh JA (1968): interactions between angiotensin, noradrenaline and serotonin on the peripheral blood vessels in man. AustJ Exp Biol Med Sci 46: 573–580.
Kubo T, Su C (1983): Effects of serotonin and some other neurohumoral agents on adrenergic neurotransmission in spontaneously hypertensive rat vasculature. Clin Exp Hypertens (A) 5: 1501–1510.
Van Nueten JM, Janssens WJ, Xhonneux R, Janssen PAJ (1988): Interaction between S2-serotonergic and a,-adrenergic receptor activities at vascular sites. J Cardiovasc Pharmacol 11 (suppl. 1): S10–S15.
Toda N, Hayashi S (1979): Age-dependent alteration in the response of isolated rabbit basilar arteries to vasoactive agents./ Pharmacol Exp Ther 211: 716–721.
Toda N, Bian K, Inoue S (1987): Age-related changes in the response to vasoconstrictor and dilator agents in isolated beagle coronary arteries. Naunyn Schmiedebergs Arch Pharmacol 336: 359–364.
Janssens WJ, Van Nueten JM (1986): The direct and amplifying effects of serotonin are increased with age in the isolated perfused kidney of wistar and spontaneously hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol 334: 327–332.
De Mey C, Vanhoutte PM (1981): Effect of age and spontaneous hypertension on the tachyphylaxis to 5-hydroxytryptamine and angiotensin II in the isolated rat kidney. Hypertension 3: 718–724.
Doyle EA, Fraser JRE, Marshall RJ (1959): Reactivity of forearm vessels to vasoconstrictor substances in hypertensive and normotensive subjects. Clin Sci 18: 441–454.
McGregor DD, Smirk FH (1970): Vascular responses to 5-hydroxytryptamine in genetic and renal hypertensive rats. Am J Physiol 219: 687–690.
Haeusler G, Finch L (1972): Vascular reactivity to 5-hydroxytryptamine and hypertension in the rat. Naunyn Schmiedebergs Arch Pharmacol 272: 101–116.
Collis MG, Vanhoutte PM (1977): Vascular reactivity of isolated perfused kidneys from male and female spontaneously hypertensive rats. Circ Res 41: 759–767.
Webb RC (1982): Increased vascular sensitivity to serotonin and methysergide in hypertension in rats. Clin Sci 63: 73s–75s
Mecca TE, Mitchell J, Bohr DF, Webb RC (1985): Effects of serotonin antagonists on blood pressure in mineralocorticoid hypertensive sheep. J Cardiovasc Pharmacol 7: 660–665.
Cummings SA, Groszmann RJ, Kaumann AJ (1986): Hypersensitivity of mesenteric veins to 5-hydroxytryptamine-and ketanserin-induced reduction of portal pressure in portal hypertensive rats. Br J Pharmacol 89: 501–513.
Heistad DD, Armstrong ML, Marcus ML, Piegors DJ, Mark AL (1984): Augmented responses to vasoconstrictor stimuli in hypercholesterolemic and atherosclerotic monkeys. Circ Res 54: 711–718.
Heistad DD, Armstrong ML, Marcus ML, Piegors DJ, Mark AL (1986): Potentiation of vasoconstrictor responses to serotonin in the limb of atherosclerotic monkeys. J Hypertension 4: S17–S21.
Kalsner S, Richards R (1984): Coronary arteries of cardiac patients are hyperreactive and contain stores of amines: a mechanism for coronary spasm. Science 223: 1435–1437.
Winkelmann RK, Goldyne ME, Linscheid RL (1976): Hypersensitivity of scleroderma cutaneous vascular smooth muscle to 5-hydroxytryptamine. Br J Dermatol 95: 51–56.
Van Nueten JM, Janssens WJ (1986): Augmentation of vasoconstrictor responses to serotonin by acute and chronic factors: inhibition by ketanserin. J Hypertension 4 (suppl. 1): S55–S59.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Van Nueten, J.M., Janssens, W.J., Janssen, P.A.J. (1990). Altered responses to 5-hydroxytryptamine in hypertension and other cardiovascular disorders. In: Saxena, P.R., Wallis, D.I., Wouters, W., Bevan, P. (eds) Cardiovascular Pharmacology of 5-Hydroxytryptamine. Developments in CardioCardiovascular Pharmacology of 5-Hydroxytryptamine, vol 106. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-0479-8_23
Download citation
DOI: https://doi.org/10.1007/978-94-009-0479-8_23
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6701-0
Online ISBN: 978-94-009-0479-8
eBook Packages: Springer Book Archive